It’s not a good day for rheumatoid arthritis and colon cancer patients looking for more treatment options. This morning Roche and Biogen Idec suspended trials of their ocrelizumab rheumatoid arthritis drug after it was linked to elevated rates of serious infections. Some of the infections were fatal. The monoclonal antibody, a successor to the popular [...]
it should be interested what change will this make